Ochre Bio develops first-in-class RNA therapies for chronic liver disease using a combination of functional genomics, machine learning and experimental biology in human cell, tissue and organ systems.Learn more at www.ochre-bio.com.

Managed strategy engagements in life sciences with a focus on commercial, R&D, data & digital.

Chief of Staff to UK Life Sciences Strategy, Analytics, M&A leadership team.

Led due diligence, execution, and management of an $85 million portfolio of nutrition and healthcare investments. Joined as early employee during fund start up. Co-led investment strategy.Invested alongside great partners at the Children’s Investment Fund Foundation, World Bank, UK DFID, Bill and Melinda Gates Foundation, private sector companies, and high net worth individuals.

Designed, launched and scaled healthcare social enterprises in Myanmar and Zambia in partnership with innovative non-profits, corporates and foundations. Led efforts to expand Living Goods' digitally-enabled health entrepreneur model through partnerships in Sub-Saharan Africa and Asia.

Led technical advisory teams supporting Ministries of Health through projects optimizing limited health sector resources and scaling social health insurance for universal health coverage.

Analyst in Global Securitized Products Group within Capital Markets and Origination. Performed credit analyses and asset backed securities structuring, and supported new business development.